View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 21, 2022

Panthera raises funds to expedite expansion of clinical trial sites

The investment proceeds will also be used to enhance Panthera's service offering.

Panthera Biosciences has received an investment of $13.04m (£10m) from BGF and Gresham House Ventures to expedite its dedicated clinical trial site network expansion.

Gresham made the investment on behalf of the Baronsmead VCTs. 

The proceeds from the investment round will aid Panthera in further expanding its network of trial sites across the UK and Western Europe.

Furthermore, the company will use the funds to continue investing in boosting the service offering.

Established in 2019 with an initial investment from Gresham and Catapult investing in 2020, Panthera is a key player in the UK with nine study sites.

On behalf of pharma firms and contract research organisations (CRO), the company enrols trial subjects and conducts clinical trials.

Panthera has developed a Site Management Organisation (SMO) model leveraging technology and trials in specialist areas including oncology, neurology, non-alcoholic steatohepatitis (NASH) and vaccines and people who receive treatment in general practice.

The oncology trials across the UK are carried out by Panthera in collaboration with the Rutherford Cancer Centres.

Panthera Biosciences chairman John Lyon said: “We are very pleased to have the backing of such reputable and respected investment houses as BGF and Gresham House Ventures, which will supercharge our expansion. 

“In the last two and a half years our management team has built an exemplar SMO model which has been welcomed by our clients in the major pharmaceutical companies and CROs. 

“In the next twelve months we aim to become the preferred provider for our clients across Europe.”

In March this year, the company received the contract to enrol participants in Roche’s double-blind, placebo-controlled Phase III clinical trial for advanced or metastatic breast cancer patients.

As per the contract, Panthera will recruit subjects from three sites in the UK in Liverpool, Reading and Newport through the collaboration with Rutherford Health.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy